Adding enzalutamide to androgen deprivation therapy significantly prolongs overall survival in men with nonmetastatic, castration-resistant prostate cancer and rapidly increasing PSA

The TERAVOLT consortium has identified patient- and treatment-related factors associated with an increased risk for death among thoracic cancer patients with COVID-19 infection

Cancer patients with COVID-19 have specific risk factors that may help contribute to a high rate of mortality

Patients with high-risk gastrointestinal stromal tumours benefit from 3 years of adjuvant imatinib

Alpelisib discontinuation rates in people with advanced HR-positive, HER2-negative breast cancer can be reduced with the use of a detailed adverse event management plan focusing on the most commonly occurring events

Phase III study data show no benefit of histology-tailored neoadjuvant chemotherapy over anthracycline plus ifosfamide in patients with localised high-risk soft tissue sarcoma of an extremity or the trunk wall

On-target adverse events associated with TRK inhibitor therapy may include weight gain and dizziness

Nivolumab achieved comparable overall survival to bevacizumab among glioblastoma patients who had previously been treated with radiotherapy and temozolomide